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selected using the PharMetrics Patient-Centric Database. All
patients were assumed to be on original therapy for the ﬁrst
month, with discontinuation rates derived from the subsequent
11-month period. Medical costs were estimated based on payer
reimbursements for all services rendered to TOL and OXY
patients matched for demographic and pretreatment clinical
characteristics. Subsequent costs for those who discontinued
therapy were based on patients receiving medical management
without drug therapy (n = 29,992). Costs for drugs were pro-
vided by AnalySource (October 2004). RESULTS: After the 
11-month follow-up period, 21% of TOL and 15% of OXY
patients remained on original therapy. Mean total health care
costs per patient were $8876/y for those originally on TOL and
$9080/y for those started on OXY. Sensitivity analyses indicated
that results were robust to changes in drug cost and probability
of discontinuation. When persistence was held equal, cost dif-
ferences continued to favor TOL: 21% = $272/year and 15% =
$233/year. Furthermore, for the model to result in equivalent
annual health care costs, TOL cost must increase by $1.50/day
or OXY cost must decrease by $1.62/day. CONCLUSIONS: At
the end of one year, OAB patients were more likely to remain on
original treatment taking TOL versus OXY. This resulted in a
total health care cost savings of $204 per patient.
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OBJECTIVE: We compared the direct health care costs for
patients receiving different prescription pharmacologic agents
for overactive bladder (OAB) symptoms in a managed care
setting. METHODS: We used administrative medical and phar-
macy claims data from >30 managed care plans. Patients newly
diagnosed with OAB who initiated treatment with tolterodine
extended release (TOL ER), oxybutynin extended release (OXY
ER), or oxybutynin immediate release (OXY IR) were followed
for 12 months from the date of initial diagnosis. Patients were
required to be continuously eligible for pharmacy and medical
beneﬁts during the study period. Total mean medical costs 
were assessed for the 12-month follow-up period and were com-
pared across the treatment groups after statistical adjustment for
age, sex, and days to treatment initiation. Medical costs were
calculated from inpatient admissions, emergency room visits,
outpatient physician visits, other prescription drugs, and diag-
nostic/laboratory services. RESULTS: A total of 6110 patients
initiated treatment with TOL ER (mean age 55y, 77% women),
3325 with OXY ER (mean age 55y, 73% women), and 893 with
OXY IR (mean age 57y, 61% women). Patients who received
OXY ER ($9063) and OXY IR ($10,523) had signiﬁcantly
higher adjusted annual mean medical costs than did patients who
received TOL ER ($8073, p = 0.0175 and p = 0.0001, respec-
tively). CONCLUSIONS: Diagnosing and managing patients
with OAB is challenging, especially as it relates to pharmacologic
treatment. Observed lower medical costs of TOL ER patients in
this study may have broad implications. Results from this study
warrant further analysis that fully incorporates adjustments for
the factors associated with treatment selection as well as disease-
speciﬁc drivers of health care costs.
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OBJECTIVE: To assess the economic impact of everolimus 1.5
mg with reduced-dose cyclosporine (CsA) vs. mycophenolate
moteﬁl (MMF2g) with full dose CsA in de novo renal transplant
recipients. METHODS: A previous trial (B201) which prospec-
tively collected resource utilization during one-year showed
similar economic outcomes for everolimus vs. MMF2g with 
full-dose CsA. Direct medical costs (excluding everolimus, 
CsA and MMF) were mostly dependent on key clinical events:
hemodialysis, length of stay (LOS) due to adverse events (AE) 
or infection (INF), biopsy proven acute rejection (BPAR) and
days on cytomegalovirus (CMV) therapy. A subsequent trial of
everolimus with reduced-dose CsA demonstrated similar efﬁcacy
(A2306). A multivariate model was ﬁtted on the B201 data to
predict direct medical costs. Coefﬁcients were then applied to the
A2306 data to predict the economic outcomes of everolimus
with reduced-dose CsA. As no signiﬁcant country-speciﬁc cost
effect on LOS was found, individual country cost vectors were
applied (Germany, France and Spain). RESULTS: For Germany,
incremental costs were 250€ per hemodialysis session (p <
0.001), 261€ per day of hospitalization due to AE (p < 0.001),
343€ per day of hospitalization due to INF (p < 0.001) and
4473€ per BPAR (p < 0.001). After adjusting for recipient age,
living donors, and CMV therapy between B201 and A2306,
everolimus with reduced-dose CsA decreased 1-year costs by
3260€ vs. MMF with full-dose CsA. Taking into account cost 
of CsA, MMF and everolimus (assuming parity pricing of
everolimus 1.5mg and MMF 2g), everolimus with reduced-dose
CsA decreased total 1-year costs in Germany by 3960€. In Spain
and France, the ﬁnal cost-savings would be 1516€ and 3217€,
respectively. CONCLUSION: In de novo kidney transplant
recipients over a 1-year follow-up period, everolimus 1.5mg 
with reduced-dose CsA is a cost-saving strategy compared to
MMF-based regimen. Further analyses in other health care set-
tings are needed to fully document the cost-saving of everolimus
1.5mg.
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OBJECTIVES: To develop a decision analytic model comparing
the cost-effectiveness of various preparations of oxybutynin 
and tolterodine in the treatment of overactive bladder (OAB).
METHODS: The model included immediate-release oxybutynin
(OxyIR), extended-release oxybutynin (OxyER), transdermal
oxybutynin (OxyTD), immediate-release tolterodine (TolIR),
and extended-release tolterodine (TolER). Treatment success was
deﬁned as complete continence (no incontinence episodes). The
model was constructed from the payer’s perspective, assuming
incontinence pads were a covered beneﬁt. The timeframe for the
model was three months. Costs included were medications,
incontinence pads, and treatment of OAB-induced morbidities
(i.e., urinary tract infections, fractures, depression, and skin
infections). The selection of clinical outcomes data was based on
the following priority: 1) FDA approval label; 2) randomized
